Datasets
Buyer room
RESCRIPTION.COMManage supplier listing
Rescription (Rexi platform) — A live, adjudication-derived pharmacy cash-price matrix, plus the decision log built on it. The Rexi claims-adjudication engine compares multiple candidate prices for every drug at over 64,000 pharmacies nationwide, drawing on guaranteed published NADAC pricing and pharmacy cash-pay pricing, and selects the lowest available price at the point of sale. The byproduct is therefore not a scraped price list but a transaction-grade price table: for each NDC and quantity, the cash and contracted prices actually available at each pharmacy, continuously refreshed by real …
supplier index read from their site
A live, adjudication-derived pharmacy cash-price matrix, plus the decision log built on it. The Rexi claims-adjudication engine compares multiple candidate prices for every drug at over 64,000 pharmacies nationwide, drawing on guaranteed published NADAC pricing and pharmacy cash-pay pricing, and selects the lowest available price at the point of sale. The byproduct is therefore not a scraped price list but a transaction-grade price table: for each NDC and quantity, the cash and contracted prices actually available at each pharmacy, continuously refreshed by real adjudications rather than periodic crawls. Alongside it sits the adjudication decision log — which pharmacy won each claim, what the rejected alternatives cost, and the size of the spread captured — which is a realized price-arbitrage record no public source provides. Member-facing lookup across 60,000+ pharmacies through the myRescription app adds a demand-side layer of member price-shopping queries, and the Saver Program, which applies point-of-sale savings to the most expensive drugs via health-system partnerships, implies negotiated or alternative price models on specialty drugs held only by this vendor.
Scale Price coverage across 64From 3 yearsCoverage Financials · Consumer Staples
Sample, licence terms, pricing and eval results when Rescription publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Rescription, answered from this page.
Rescription (Rexi platform) — A live, adjudication-derived pharmacy cash-price matrix, plus the decision log built on it. The Rexi claims-adjudication engine compares multiple candidate prices for every drug at over 64,000 pharmacies nationwide, drawing on guaranteed published NADAC pricing and pharmacy cash-pay pricing, and selects the lowest available price at the point of sale. The byproduct is therefore not a scraped price list but a transaction-grade price table: for each NDC and quantity, the cash and contracted prices actually available at each pharmacy, continuously refreshed by real …
Rescription offers (Alternative, Price, Reference) — Price coverage across 64,000+ pharmacies nationwide per drug, with multiple candidate prices evaluated per claim — combined with the commercial NDC universe, this is a combinatorially large price matrix, though the resolvable grid is sparse in practice since not every pharmacy stocks every drug. The adjudication event log scales with the book of business and is undisclosed in volume. Member lookup spans 60,000+ pharmacies. Exact counts of stored price observations, refresh cadence and retained claims volume are not published and must be requested..
Independent validation of PBM and pharmacy cash pricing, which is otherwise self-reported and unverifiable — the arbitrage log is an empirical measure of what price was actually achievable at the counter; pharmacy price-competitiveness benchmarking and referral routing by NDC and geography; employer and plan-sponsor pharmacy benefit audit, testing whether an incumbent PBM's pricing left money on the table; prescription-price index construction and inflation tracking at pharmacy level rather than national-average level; antitrust, litigation and regulatory-economics evidence on pharmacy and PBM pricing behavior; PBM contract design and alternative price-model testing; specialty-drug affordability program design through the Saver Program's high-cost drug mechanisms; and equity-research alpha on retail pharmacy chains, since a transaction-grade read of which chains are genuinely undercutting on cash prices is a margin signal visible ahead of reported results.
The data is with 3 years of history.
Coverage spans US; Managed Care, Drug Retail; alternative, price, reference; equities.
Rescription has not added their own details yet. Not yet on file: